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Abstract: Atrial fibrillation is a common arrhythmia in heart failure and a risk factor for 
stroke. Risk assessment tools can assist clinicians with decision making in the allocation of 
thromboprophylaxis. This review provides an overview of current validated risk assessment 
tools for atrial fibrillation and emphasizes the importance of tailoring individual risk and 
the importance of weighing the benefits of treatment. Further, this review provides details of 
innovative and patient-centered methods for ensuring optimal adherence to prescribed therapy. 
Prior to initiating oral anticoagulant therapy, a comprehensive risk assessment should include 
evaluation of associated cardiogeriatric conditions, potential for adherence to prescribed therapy, 
frailty, and functional and cognitive ability.
Keywords: stroke risk, heart failure, atrial fibrillation, anticoagulation, risk stratification, 
medication adherence
Introduction
Heart failure (HF) is a complex and primarily cardiogeriatric syndrome.1 One-third of 
patients with HF are likely to have atrial fibrillation (AF) as a concomitant condition.2 
AF is a predictor of stroke in patients with HF.3 Therefore, predicting and treating the 
risk of stroke with definitive therapies, including antithrombotics, is highly justified 
and recommended by best practice guidelines.4–6 Yet, commonly these therapies are not 
applied in practice.7 Under 70% of estimated eligible patients receive anticoagulation 
therapy.7
Although the use of anticoagulants has increased in the past 2 decades,8 those 
individuals considered to be at an increased risk of bleeding are less likely to be 
prescribed anticoagulation therapy.8 As a consequence, patients may not be receiving 
therapy based purely upon their predicted stroke risk alone. Many factors contribute 
to clinical decision making amongst physicians that influence prescription.9,10 Factors 
such as cognitive impairment and frailty are common reasons for clinicians choosing 
not to prescribe thromboprophylaxis.11,12
This is a clinical conundrum for health professionals in prescribing evidence-based 
therapy and deciding if the risk of treatment outweighs the risk of nontreatment.13 
The Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) trial compared 
dose-adjusted warfarin with 75 mg aspirin in elderly patients over 75 years. The 
investigators found that warfarin was associated with a significant reduction in stroke 
with no difference in the risk of significant hemorrhage.14 However, the Warfarin and 
Aspirin in Patients with Heart Failure and Sinus Rhythm (WARCEF) study,15 although 
conducted in people with sinus rhythm and not AF, showed that the benefit of warfarin 
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in reducing ischemic stroke was offset by an increased risk 
of major hemorrhage.15 Underpinning the choice to prescribe 
thromboprophylaxis should be one that is individualized to 
the risk of the patient.
This review provides a critique of current risk assessment 
tools for the evaluation of stroke and bleeding risk in AF. 
Further, it identifies the need to extend these assessments 
to factors that impact treatment adherence and to consider 
risks for adverse events, particularly bleeding. Strategies 
for promoting adherence to prescribed therapy are also 
included.
Stroke and bleeding risk  
assessment schemata in AF
Risk classification schemata are intended to guide treatment 
decisions in AF by defining the likelihood of future clinical 
events based on independent risk factors.13 Risk scores can 
be used to estimate the absolute risk of an adverse event. 
This may be helpful in counseling patients and informing 
treatment decisions.16 These metrics do not consider the 
balance of risk of adverse events and potential nonadherence. 
The CHADS
2
 (congestive heart failure, hypertension, 
age $ 75 years, diabetes mellitus, prior stroke, transient 
ischemic attack, or thromboembolism) score (Table 1) was 
derived from the Atrial Fibrillation Investigators’ and Stroke 
Prevention in Atrial Fibrillation Investigators’ schemata. 
This was validated in a retrospective cohort of hospitalized 
patients with AF. A score of zero identified patients at low 
stroke risk. A score of one to two identified patients at 
moderate stroke risk. A score greater than two identified 
patients at high stroke risk.17,18 Patients with two or more 
points are predicted to have an annual stroke risk of over 4%, 
whereas those scoring no points have a predicted annual risk 
of less than 1%–2%.18
The Stroke Prevention in Atrial Fibrillation (SPAF) 
scheme estimates risk based upon the presence of the 
following risk factors alone or in combination: age, female 
sex, diabetes, previous stroke or transient ischemic attack, 
hypertension, or elevated systolic blood pressure.19,20 
Similarly, the Framingham scheme can be used to risk assess 
stroke risk through the assignment of values to each of the 
following well-established independent risk factors: age, 
gender, systolic blood pressure, diabetes, and prior stroke 
or transient ischemic attack.16,20 The CHADS
2
, SPAF, and 
Framingham schemes have demonstrated greater predictive 
accuracy than chance.20 This predictive ability may allow 
clinicians to target high-risk patients for more aggressive 





heart failure, hypertension, age $ 75 years, diabetes mellitus, 
prior stroke, transient ischemic attack, or thromboembolism, 
vascular disease, age 65–74 years, sex category) score, 
provides the highest sensitivity of all schemes to predict 
thromboembolism (Table 1).21
A number of bleeding risk stratification tools exist. 
Amongst these are the HEMORR
2
HAGES (hepatic or renal 
disease, ethanol abuse, malignancy, older age, reduced platelet 
count, rebleeding risk, anemia, genetic factors, excessive falls 
risk, stroke)22 and the HAS-BLED (hypertension, abnormal 
renal/liver function, stroke, bleeding history or predisposition, 
labile international normalized ratio [INR], elderly, drug/
alcohol concomitantly)23 tools, yet these are not often used in 
clinical practice and use is cumbersome. Many use complex 
scoring systems, and few have been validated in patients with 
AF and HF. The HAS-BLED bleeding risk tool originated 
in 2011 and was validated in a European cohort of 3978 
participants with AF (Table 2). In a comparative validation, 
the HAS-BLED tool displayed an increased predictive ability 
than four other bleeding risk stratification methods22,24–26 
among patients in the combined Stroke Prevention Using 
Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) 
III and V cohort.23 Following validation, the HAS-BLED 
tool was suggested as a simple, yet easy to calculate tool 
Table 1 Stroke risk stratification with CHADS2 and CHA2DS2-
VASc assessment tools





Congestive heart failure 1 0 1.9%
Hypertension 1 1 2.8%
Aged $ 75 years 1 2 4.0%
Diabetes mellitus 1 3 5.9%
Stroke/TIA 2 4 8.5%
Max score 6 5 12.5%
6 18.2%
CHA2DS2-VASc acronym
Congestive heart failure/ 
LV dysfunction
1 0 0%
Hypertension 1 1 0.7%
Aged $ 75 years 2 2 1.9%
Diabetes mellitus 1 3 4.7%
Stroke/TIA/TE 2 4 2.3%
Vascular disease (prior to  
MI, PAD, or aortic plaque)
1 5 3.9%
Aged 65–74 years 1 6 4.5%
Sex category (ie, female  
gender)
1 7 10.1%
Max score 10 8 14.2%
9 100%
Abbreviations: LV, left ventricular; MI, myocardial infarction; PAD, peripheral 
artery disease; TE, thromboembolism; TIA, transient ischemic attack.
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that can be used to assess bleeding risk in AF patients within 
everyday clinical practice.13 A HAS-BLED score of at least 
three indicates high risk and the developers of the tool suggest 
the need for regular review and some caution following the 
initiation of oral anticoagulant or aspirin therapy.13
Adherence
Failing to adhere to recommendations is a major reason 
for adverse events.27 Adherence is a multidimensional 
phenomenon determined by the relationship of five series 
of factors or dimensions. There are f ive dimensions 
within the World Health Organization’s multidimensional 
adherence model, which incorporate socioeconomic-, health 
care system-, condition-, treatment-, and patient-related 
factors;28 this model assists in providing a framework for the 
organization of barriers to anticoagulant therapy (Table 3). 
Implications for practice including strategies that may be 
employed to improve adherence are also provided.
Once the need for oral anticoagulation is identified, 
several additional factors must be considered. Despite the 
evidence demonstrating the benefits of anticoagulation 
therapy in AF and HF, adherence to these recommendations 
is far from optimal.10,29,30 The hesitation to anticoagulate 
patients is often based upon fear of adverse effects and poor 
adherence with monitoring, and this is most pronounced in 
the elderly.12 The need for monitoring and titration as well as 
the adverse effect profile likely contributes to this reticence.31 
Although the use of newer agents such as oral direct thrombin 
inhibitors (eg, dabigatran) and oral factor Xa inhibitors 
(eg, rivaroxaban and apixaban) show particular promise in 
decreasing monitoring, concerns regarding adherence and 
adverse events remain high.13 Despite data describing the 
barriers and facilitators to thromboprophylaxis in the elderly, 
there has been a lesser focus on individuals with HF who are 
at high risk.12 New approaches, that are patient centered, are 
required to enhance evidence-based use of therapy to prevent 
thromboembolism and identify risk of bleeding.32
Health system-related factors
Clinical trials and meta-analyses have demonstrated the effect 
of anticoagulation in reducing the risk of ischemic stroke in 
patients with AF.33–37 Yet, a large proportion of patients with 
AF are not treated with anticoagulant therapy. Despite the 
well-recognized association between AF and prevention of 
ischemic stroke and the benefits of therapy, anticoagulant 
therapy remains underused in AF patients.7 There are 
numerous reasons why anticoagulant therapy is not initiated, 
but it is largely due to clinician and patient concerns about 
the risk of falls and hemorrhagic complications.7 Clinicians 
may be apprehensive about initially prescribing oral 
anticoagulants to elderly patients given the concerns about 
a higher risk of oral anticoagulant-associated hemorrhage.38 
Table 2 The HAS-BLED score
Clinical characteristic Score HAS-BLED score Bleeds per 100 patient-years
Hypertension 1 point 0 1.13
Abnormal liver or kidney function 1 point each (1 or 2) 1 1.02
Stroke 1 point 2 1.88
Bleeding 1 point 3 3.74
Liable international normalized ratios 1 point 4 8.70
Elderly 1 point
Drugs or alcohol 1 point each (1 or 2); 
max 9 points
Notes: Hypertension = systolic blood pressure . 160 mmHg; abnormal renal function = dialysis/renal transplantation/serum creatinine . 200 mmol/L; abnormal liver 
function = chronic hepatic dysfunction (eg, cirrhosis) or biochemical evidence of significant hepatic derangement (eg, bilirubin twice the upper limit of normal in association 
with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase three times the upper limit of normal); bleeding = history of bleeding or a bleeding diathesis; 
drugs = concomitant use of antiplatelet or nonsteroidal antiinflammatory drugs.
Table 3 Barriers to thromboprophylaxis
Health system-related factors Clinician apprehension  
Fear of intracranial hemorrhage  
and falls 
Lack of multidisciplinary approach 
Urban versus rural resource barriers




Socioeconomic-related factors Cost of medication 
Cost of visiting clinics 
Ability to attend clinics
Patient-related factors Level of cognition 
Medication and condition knowledge 
Language difficulties 
Inadequate patient education
Condition-related factors Polypharmacy 
Frailty 
Cognitive and functional impairment 
Stress and depression
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Of 4188 patients in the Anticoagulation and Risk Factors in 
Atrial Fibrillation (ATRIA) study with AF who were newly 
commenced on warfarin therapy, more than one-quarter of 
patients had discontinued treatment after 1 year.39 The study 
authors hypothesized that this may have been due to difficulty 
in INR control or concerns from clinicians or patients about 
bleeding risk.39 More recently, in a Swedish atrial fibrillation 
cohort study, in almost all patients within a large cohort 
of 182,678 patients with AF, the risk of ischemic stroke 
without anticoagulant treatment was higher than the risk of 
intracranial bleeding with anticoagulant treatment.40
Solution to health system-related 
factors
Clinician apprehension may be reduced through providing 
training and education and practical clinical practice guidelines 
that provide support for clinical decision making.41–43 The 
additional use of a bleeding prediction tool (eg, HAS-BLED) 





may also assist in clinical decision making.13 Undertaking 
chart reviews and clinical audits and excluding patients with 
documented contraindications to therapy may assist in the 
identification of patients who are eligible for oral anticoagulant 
therapy; however, this is not prescribed as a method to 
increase uptake.44 From a wider health systems perspective, 
having access to a state or national surveillance system or the 
development of a national AF and anticoagulation registry is 
advocated.41,45 Clinician adherence to guidelines is a complex 
issue.46 Cabana et al offer a range of barriers why clinicians don’t 
follow guidelines. They include barriers affected by clinician 
knowledge (eg, lack of awareness or lack of familiarity), 
attitudes (lack of agreement, lack of self-efficacy, lack of 
outcome expectancy, or the inertia of previous practice), or 
behavior.47 A way to improve clinician adherence to guidelines 
may include developing specialized anticoagulation clinics 
with expert nurses and doctors as a way to reduce clinician 
apprehension when commencing patients on oral anticoagulant 
therapy.48 This warrants further exploration.
Treatment-related factors
Both the efficacy and safety of warfarin therapy are strongly 
correlated with therapeutic dosages.49 An INR of 2.0–3.0 
is well established as a therapeutic target range for stroke 
prevention in AF;50,51 therefore, time that a patient spends 
within their range of target INR should be maximized.50,52 
A major concern is intracranial hemorrhage, which is 
associated with high morbidity and mortality.53,54 Novel 
anticoagulants appear to have a more favorable safety profile 
than warfarin, as evident through large clinical trials.55–57 One 
of the foremost attractions of such novel agents including 
oral direct thrombin inhibitors and factor Xa inhibitors over 
warfarin is that they have predictable pharmacokinetics, 
therefore reducing or eliminating the burden of routine 
anticoagulation monitoring. Nevertheless, reversal of such 
newer agents can be complex and problematic.58
Solutions to treatment-related 
factors
In patients with normal kidney function and an estimated 
glomerular filtration rate . 30 mL/minute, thromboprophylaxis 
should be selected accordingly after a comprehensive clinical 
assessment. Dabigatran and rivaroxaban are excreted by the 
kidneys (dabigatran 80% and rivaroxaban 66%), therefore 
dosage may require adjustment according to estimated 
glomerular filtration rate.59
Many patients continue to be prescribed warfarin therapy, 
requiring them to have their INR monitored, which can be 
burdensome.7 Health infrastructure must be supportive and 
enabling of this need for surveillance. Ensuring regular INR 
monitoring to maintain therapeutic targets and avoid adverse 
events is critical.38 Rural outreach or metropolitan hospital 
liaison services and dedicated anticoagulation clinics are 
one such approach to achieve these goals.41 INR self-check 
kits are an effective strategy to encourage patients with self-
care.60 However, patients must be able, well-informed, and be 
supplied with a coagulometer.60 Although providing financial 
incentives to patients to attend clinics or visit clinicians to 
increase attendance rates is novel, uptake is low.61
Socioeconomic-related factors
The annual cost of anticoagulation with warfarin is estimated 
to be £207.30 in comparison to £1573.50 with the novel 
anticoagulant dabigatran (per patient; excluding the cost of 
INR monitoring).62 The high cost of medication can prohibit 
initial purchase and continuation of therapy. In some instances 
this may lead to doses skipped in order to save money.63 
Costs associated with visiting a primary care physician or 
other member of the multidisciplinary health care team may 
discourage essential follow-up visits. It is essential to monitor 
the effectiveness of therapy. These factors may prohibit 
optimal care and outcomes of oral anticoagulation therapy.
Solutions to socioeconomic- 
related factors
Several suggested solutions have been offered to deal 
with such barriers. These include the use of innovative 
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technologies like self-check INR kits to undertake self-care at 
home. This limits the need for frequent visits to primary care, 
though this may be an expensive appliance which the patient 
may have to purchase and maintain.60 A level of cognitive 
capacity and knowledge is required to interpret results and 
respond to these in an appropriate manner.64 Point of care 
and health rebate systems as well as monitoring pharmacy 
refill records may assist in the uptake and maintenance of 
therapy.41
Patient-related factors
Medication adherence in HF is a poorly understood yet 
fundamental aspect of patient care.65 Medication adherence 
rates within the HF population vary widely.66 Patients are 
required to balance the need for prescribed medication 
against any perceived adverse drug event, which may lead 
to nonadherence or permanent discontinuation of use of oral 
anticoagulant medications.67 Such suboptimal drug use is 
associated with an increase in unplanned hospital admissions, 
increased mortality and morbidity rates, and accompanied by 
additional health care-related costs.68 It has been estimated 
that patients who do not take their medications as prescribed 
costs the US health care system $290 billion in avoidable 
health-related spending every year.69
Solutions to patient-related barriers
The World Health Organization emphasizes that despite 
the vast amount of knowledge that exists around adherence 
issues, efforts to address the problems have been divided 
and – with a few exceptions – have failed to encapsulate the 
potential contributions of the diverse health disciplines.28 The 
World Health Organization advocates that a stronger buy-in 
and commitment to a multidisciplinary model is required in 
order to make progress in the area of poor adherence.28
Poor patient education is a commonly cited problem 
contributing to poor adherence.43 Patient knowledge is 
a determinant of anticoagulation control.43 A lack of the 
perception of medication importance, risk of adverse events, 
irregular monitoring of serum INR, or a lack of the perception 
of risk-to-benefit threshold may lead to adverse events.43 
Inadequate self-management counseling and language 
difficulties also contribute to this multifaceted issue.70 
Bajorek et al advocate that a pharmacist-led multidisciplinary 
process within the hospital setting may increase overall 
antithrombolytic therapy use.71 Simplified drug regimes and 
improved case management comprising of patient education 
and discharge counseling may be of value.71 This must 
address the behaviors and preferences of individual patients. 
Interventions that target the elderly and those with poor 
literacy are vital.72 Such strategies may include providing 
pamphlets and printed materials with colors, pictures, and 
visual aids, the enlargement of materials, compact disc 
read-only memory (CD-ROM) or spoken materials, structured 
educational programs, the mailing of educational materials, 
or even online resources and social media patient education 
interventions.41 Explicit instructions to primary care providers 
at patient discharge from acute care, patient reminder cards, 
and patient forums that provide peer support may be of help.41 
Telemonitoring may prove an effective method to improve 
medication adherence for HF patients at home. It was recently 
reported that HF patients using structured telephone support 




Polypharmacy and comorbidity are fundamental factors that 
affect medication adherence. Patients with HF and AF may be 
using antiplatelet therapy74 or are likely to have concurrent use 
of multiple medications with antihypertensive properties that 
predispose patients to symptomatic orthostatic hypotension, 
syncope, or falls.75 Being at an increased risk of falling 
may inevitably lead to an increased risk of hemorrhage, 
particularly intracranial if a head injury is sustained during 
a fall due to syncope. There are many explanations for an 
increased risk of falling. This may only be perceived by the 
clinician because of age.75 However, this may be attributable 
to gait,76 cognitive impairment, or dementia.43 Anticoagulant 
therapy should not be denied based on age alone.75
Dietary restrictions
Patients may have dietary restrictions or preferences. This 
may affect pharmacokinetics and may lead to suboptimal 
coagulation and impact time spent in a therapeutic range.67
Associated condition burden
Frailty,12 cognitive and functional impairment,11 stress,70 and 
depression77 are all conditions associated with HF and AF. 
These conditions may lead to failure to adhere to appropriate 
INR monitoring or reduced adherence through the cognitive 
or physical inability to self-administer oral medications. 
Comparable to patients with cognitive decline, there is 
evidence that patients with mental health conditions and AF 
are less likely than those without mental health conditions 
to have adequate AF management.78 Depression has been 
identified as a moderately common condition in HF,79 and 
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was associated with poor medication compliance in the Heart 
and Soul Study.77
Solutions to condition-related 
factors
Polypharmacy and falls
Clinicians ought to assess the risk of falls using reliable and 
valid methods. Planning fall minimization interventions 
should be in collaboration with the multidisciplinary 
team.44 Assessment of any underlying conditions including 
neuropathy, frailty, and cognitive concerns should be 
investigated.80 Cognitive ability can be evaluated using 
reliable and validated and readily accessible measures such 
as the Mini Mental State Examination or The Montreal 
Cognitive Assessment.81
The use of once-daily medication formulations or 
polypills may aid improved adherence.82 Whilst this 
may be achievable with HF treatments where doses of many 
medications remain consistent once up-titrated, this may 
present difficulties in AF with varying dosages of certain 
anticoagulants and the need to regularly adjust dosage 
according to the INR.
Dietary restrictions
Clinicians must ensure that a dietician consultation with 
specific dietary advice regarding vitamin K intake occurs. 
This may occur via telephone consultations or clinic visits. 
This is a simple yet imperative strategy that may reduce the 
risk of inadequate anticoagulation. Patients altering their 
dietary intake of green leafy vegetables should be encouraged 
to notify their clinician as their dosage of warfarin may 
require adjustment.83
Monitoring adherence
Patient self-reporting is a useful method of assessing 
medication adherence. Self-reporting offers reliable predictors 
of a broad array of cardiovascular health outcomes – including 
blood pressure control, hospitalization for HF, and serum 
drug concentrations – that are highly applicable to this 
group of patients.77 There are a number of tools available 
to measure self-reported adherence. The Morisky Scale 
provides good predictive ability and can be easily integrated 
as part of a comprehensive patient assessment prior to the 
commencement of any oral anticoagulant therapy.84
Associated condition burden
Although there are numerous risk stratif ication tools 
available to assist clinicians in allocating treatments, they 
do not consider frailty, which impacts adversely on health 
outcomes.12 Cognitive and functional decline are significant 
consequences of both HF and AF.85 Undertaking a formal 
frailty assessment may assist in the guidance of prescribing 
of oral anticoagulants and may help clinicians identify 
patients who are at increased risk of adverse events from 
anticoagulant therapy.12 Further investigation is warranted 
to examine the causal relationship between depression and 
adherence particularly in the HF and AF patient population. 
Where depression exists, the inclusion of a mental health 
clinician in the multidisciplinary care model providing care 
to the patient may be of benefit.74
Enhanced models for stratifying bleeding risk particularly 
in the frail population are required.45 Frailty assessment 
tools that currently exist could be used as an adjunct to 
any stroke risk prediction tool. Any new models or frailty 
assessment criteria should additionally be incorporated into 
clinical practice guidelines.45 Strategies that aim to reduce 
or manage falls including assistance from family, relatives, 
informal caregivers, or the provision of home help should 
not be overlooked.
Implications for clinical practice
Further research is required to examine the issue of 
anticoagulant therapy in patients with HF and AF. This is 
driven by population growth in the elderly and the increasing 
burden of the cardiogeriatric population.86,87 Available data 
suggest it may be useful to include a risk assessment of 
other aspects of a patient’s life as opposed to the restrictive 
tools that currently exist. Nonadherence with medication 
and other lifestyle recommendations is a major problem in 
patients with HF and has severe consequences for individual 
patients as well as for the health care system.88 Treatment 
and care should take into account patients’ individual needs 
and preferences. However, most people with AF should 
be considered for treatment with oral anticoagulants based 
on their risk of stroke, ability to tolerate anticoagulation 
without bleeding, and access to adequate anticoagulation 
monitoring.
Although there are robust stroke prediction tools, they 
cannot be considered external to a cardiogeriatric assessment. 
Extending and developing these tools to consider the risk 
of nonadherence to prescribed therapy and poor adherence 
are warranted. Currently, there is no comprehensive risk 
assessment tool that includes criteria that assesses or 
addresses the psychosocial aspects of a patient’s ability 
to comply with anticoagulant therapy as well as the risk 
of stroke. Although novel agents offer promise, they still 
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confer risk and do not negate the importance of individual 
monitoring.
Conclusion
Current stroke risk prediction tools are useful, yet limited, 
within the context of complex cardiogeriatric syndromes. 
Expanding these to consider frailty, cognitive and functional 
decline, or nonadherence to therapy is warranted. Although 
avoiding stroke is an important consideration, the potential 
adverse effects of treatment needs to be balanced within the 
context of best available evidence, clinical expertise, and the 
individual patient’s circumstances.89 Developing metrics that 
consider the combination of these factors are likely to shed 
light on the issues of adherence in this population.
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